<
 
 
 
 
>
hide
You are viewing a Web site, archived on 18:03:13 Oct 19, 2004. It is now a Federal record managed by the National Archives and Records Administration.
External links, forms, and search boxes may not function within this collection.
FDA Logo links to FDA home page
Center for Biologics Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Biologics Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CBER A-Z Index | CBER Search | Contact CBER | CBER Home Page

horizonal rule
CBER links to product areas
CBER links
horizonal rule

Consumer / Healthcare Information

Adverse Event Reporting
  - Biological Product Deviation Reporting
  - MedWatch
  - Transfusion / Donation Related Fatalities
  - Vaccine Adverse Event Reporting System

All About Vaccines for Kids

Clin Investigator Info

Counterfeit Initiative

Countering Bioterrorism

FAQs
  - General
  - Blood
  - Vaccines

FDA Patient Safety News

Healthcare Letters

Keeping Blood Transfusions Safe

NIH Clinical Trials Database

NLM MEDLINEplus Health Information

Product Approvals

Product Labeling

Product Shortages

Recalls / Withdrawals

Safety Information

Vaccines Provide Effective Protection

Violative Advert / Promo Letters

Warning Letters
  - Other Compliance Actions

FDA Information
  - Consumers
  - Consumer Magazine
  - Health Professionals
  - Patients

 

CBER is responsible for ensuring the safety and efficacy of blood and blood products, vaccines, allergenics, and biological therapeutics. CBER's regulation of biological products has expanded in recent years to include a wide variety of new products such as biotechnology products, somatic cell therapy and gene therapy, and banked human tissues.

If you have questions or are unable to find the information you need, please contact:

Center for Biologics Evaluation and Research
Office of Communication, Training & Manufacturers Assistance
800-835-4709 or 301-827-1800
octma@cber.fda.gov

 

Transfer of Therapeutic Products to CDER

 

FDA Advances Consumer Health and Safety in 2003

 
horizonal rule